Binding of Organometallic Ruthenium(II) Anticancer Compounds to Nucleobases: A Computational Study

被引:34
|
作者
Gossens, Christian [1 ]
Tavernelli, Ivano [1 ]
Rothlisberger, Ursula [1 ]
机构
[1] Ecole Polytech Fed Lausanne, Inst Sci & Ingn Chim, CH-1015 Lausanne, Switzerland
来源
JOURNAL OF PHYSICAL CHEMISTRY A | 2009年 / 113卷 / 43期
基金
瑞士国家科学基金会;
关键词
IN-VITRO; ANTITUMOR DRUGS; ARENE COMPLEXES; PTA COMPLEXES; DNA-BINDING; CANCER; INHIBITION; MECHANISMS; CISPLATIN; LIGAND;
D O I
10.1021/jp903237w
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
The reaction of the anticancer compound [(eta(6)-benzene)Ru(en)(OH2)](2+) (1) toward the nucleobases guanine, adenine, and cytosine is studied computationally using DFT/BP86 calculations. The aqua leaving group of such compounds is known to undergo ligand exchange reactions with nucleophilic centers in DNA and preferentially with the N7 atom of guanine, N7(G). Our results show that an H-bonded reactant adduct with nucleobases is formed via either the aqua ligand (cis adduct) or the en (ethylenediamine) ligand (trans adduct) of 1. All studied nucleobases favor an H-bonded cis adduct. Only guanine forms also a trans reactant adduct in the gas phase. The guanine N7 and O6 atoms in this trans adduct are situated in an ideal position to form each a strong H-bond to both amino groups of the en ligand of 1. A docking study shows that this unique recognition pattern is also plausible for the interaction with double stranded DNA. For the reaction of 1 with guanine, we identified three different reaction pathways: (i) A cis (G)N7-Ru-OH2 transition state (TS). (ii) A direct trans reaction pathway. (iii) A 2-step trans mechanism. The activation energies for the cis pathway are smaller than for the trans pathways. The ultimately formed Ru-N7(G) product is characterized by a thermally stable H-bond between the O6(G) and a diamine-NH2 hydrogen.
引用
收藏
页码:11888 / 11897
页数:10
相关论文
共 50 条
  • [1] Structural and energetic properties of organometallic ruthenium(II) diamine anticancer compounds and their interaction with nucleobases
    Gossens, Christian
    Tavernelli, Ivano
    Rothlisberger, Ursula
    JOURNAL OF CHEMICAL THEORY AND COMPUTATION, 2007, 3 (03) : 1212 - 1222
  • [2] A Computational approach toward organometallic ruthenium(II) compounds with tunable hydrolytic properties
    Kuznetsov, Aleksey E.
    Thomet, Franz A.
    CHEMICAL PHYSICS, 2022, 560
  • [3] Development of organometallic ruthenium(II) anticancer (RAPTA) drugs
    Ang, Wee Han
    CHIMIA, 2007, 61 (04) : 140 - 142
  • [4] Anticancer evaluation of new organometallic ruthenium(II) flavone complexes
    Khater, Mai
    Brazier, John A. A.
    Greco, Francesca
    Osborn, Helen M. I.
    RSC MEDICINAL CHEMISTRY, 2023, 14 (02): : 253 - 267
  • [5] Cyclopentadienyl-Ruthenium(II) and Iron(II) Organometallic Compounds with Carbohydrate Derivative Ligands as Good Colorectal Anticancer Agents
    Florindo, Pedro R.
    Pereira, Diane M.
    Borralho, Pedro M.
    Rodrigues, Cecilia M. P.
    Piedade, M. F. M.
    Fernandes, Ana C.
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (10) : 4339 - 4347
  • [6] Organometallic Ruthenium(II) Arene Compounds with Antiangiogenic Activity
    Nowak-Sliwinska, Patrycja
    van Beijnum, Judy R.
    Casini, Angela
    Nazarov, Alexey A.
    Wagnieres, Georges
    van den Bergh, Hubert
    Dyson, Paul J.
    Griffioen, Arjan W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (11) : 3895 - 3902
  • [7] Ruthenium(II) arene anticancer complexes: Selective recognition of nucleobases and control of hydrolysis rates
    Fernandez, R
    Melchart, M
    Van Der Geer, E
    Wang, FY
    Habtemariam, A
    Sadler, PJ
    JOURNAL OF INORGANIC BIOCHEMISTRY, 2003, 96 (01) : 130 - 130
  • [8] Organometallic ruthenium(II) scorpionate as topo IIα inhibitor; in vitro binding studies with DNA, HPLC analysis and its anticancer activity
    Khan, Rais Ahmad
    Arjmand, Farukh
    Tabassum, Sartaj
    Monari, Magda
    Marchetti, Fabio
    Pettinari, Claudio
    JOURNAL OF ORGANOMETALLIC CHEMISTRY, 2014, 771 : 47 - 58
  • [9] Organometallic Anticancer Compounds
    Gasser, Gilles
    Ott, Ingo
    Metzler-Nolte, Nils
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (01) : 3 - 25
  • [10] Ruthenium(II) Arene Compounds as Versatile Anticancer Agents
    Renfrew, Anna
    CHIMIA, 2009, 63 (04) : 217 - 219